The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients.
Biomarker; Interstitial lung disease; Vascular endothelial growth factor
Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Atienza-Mateo B, Mora Cuesta VM, Iturbe Fernández D, et al. Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. Biomedicines. 2021 May;9:458.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6659
This item appears in following collections
- HVH - Articles científics 
The following license files are associated with this item: